BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...the proteins involved in the process have begun to be uncovered. One of those proteins, GPX4...
...a strategy to combat cancer, and GPX4 inhibition could be one way to do so. GPX4...
...and T lymphocyte attenuator CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 GPX4 - Glutathione peroxidase 4...
BioCentury | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BioCentury | Apr 22, 2019
Distillery Therapeutics

GPX4 inhibitors for ovarian and renal clear cell carcinomas

...DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer; renal cancer Cell culture and mouse studies identified GPX4 inhibitors...
...887 human cancer cell lines, including ovarian and renal cancer lines, identified three tool compound GPX4...
...carcinoma lines, four human ccRCC lines and two patient-derived ccRCC cell lines, two of the GPX4...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...controlling oxidation. The NADPH oxidase NOX4, which generates reactive oxygen species, and the glutathione peroxidase GPX4...
...a dual NOX1 and NOX4 inhibitor, is in preclinical testing for prostate cancer. Abstracts mentioning GPX4...
...domain containing 5 DHFR - Dihydrofolate reductase FOXC2 (MFH-1) - Forkhead box C2 GPX4 - Glutathione peroxidase 4...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Nov 30, 2017
Clinical News

Sound reports Phase Ib data for SPI-1005 in Meniere's disease

In October, Sound Pharmaceuticals Inc. (Seattle, Wash.) reported top-line data from a Phase Ib trial in 40 patients with Meniere’s disease showing that oral ebselen (SPI-1005) for 21 days improved low frequency hearing in 55%...
BioCentury | Nov 17, 2017
Company News

Monopar acquires cancer candidate from Gem, raises $9.7M

Cancer company Monopar Therapeutics Inc. (Northbrook, Ill.) said it acquired candidates including GPX-150 from Gem Pharmaceuticals LLC (Pelham, Ala.) and closed $9.7 million in financing. Gem invested $5 million. Monopar raised the remainder in two...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Cancer

...INDICATION: Cancer; solid tumors Cell culture and mouse studies suggest inhibiting GPX4 could help treat relapsing...
...treat relapsing, drug-resistant cancers. In human breast, lung, melanoma and ovarian cancer cell lines, a GPX4...
...for at least two weeks compared with normal GPX4 expression. Next steps could include testing GPX4...
BioCentury | Nov 2, 2017
Preclinical News

Researchers suggest GPX4 inhibition to treat drug-resistant cancer

...persister cells from a range of cancers depend on glutathione peroxidase 4 (GPX4) for survival, suggesting that inhibiting GPX4...
...sensitive to GPX4 inhibition than parental cells lacking resistance mechanisms. In the cell lines, a GPX4...
...The authors said development of a "potent bioavailable GPX4 inhibitor is an urgent priority," as GPX4...
Items per page:
1 - 10 of 69